Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Cyramza ® (ramucirumab)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Rationale for FOLFIRI Control Arm
When the RAISE trial was initiated, FOLFIRI was selected as the control arm because at that time
oxaliplatin- and irinotecan-based treatments were considered equally effective and interchangeable for the first- and second-line treatment of mCRC
FOLFIRI was a globally-accepted standard of care in the second-line setting after progression on an oxaliplatin-based first-line treatment regimen, and
there was no standard combination of targeted therapy plus FOLFIRI after progression on an oxaliplatin plus bevacizumab regimen.1,2
Study Design
The RAISE trial was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that evaluated FOLFIRI and ramucirumab vs FOLFIRI and placebo in the second-line treatment of patients with mCRC who had progressed on first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Patients were randomly assigned in a 1:1 ratio (stratified by region, KRAS mutation status, and time to PD after beginning first-line treatment) to receive IV infusions of either FOLFIRI plus ramucirumab 8 mg/kg (n=536) or FOLFIRI plus placebo (n=536) once every 2 weeks.3
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Colon Cancer (version 2.2015, 03Oct2014). http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 22Dec2014.
2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D on behalf of the ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii1-iii9. http://dx.doi.org/10.1093/annonc/mdu260
3. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499-508. http://dx.doi.org/10.1016/S1470-2045(15)70127-0
Glossary
FOLFIRI = irinotecan, folinic acid, and 5-fluorouracil
IV = intravenous
KRAS = Kirsten rat sarcoma virus
mCRC = metastatic colorectal cancer
PD = progressive disease
Datum fӧr senaste ӧversyn 2020 M10 01